At a glance
- Originator Roche Palo Alto LLC
- Class Piperazines; Pyrimidinones; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 09 Nov 2006 Discontinued - Preclinical for Benign prostatic hyperplasia in USA (unspecified route)
- 09 Dec 2003 No development reported - Preclinical for Benign prostatic hyperplasia in USA (unspecified route)
- 08 Aug 2000 New profile